alexa Advances In Targeted Cancer Therapy
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th International Conference on Medicinal Chemistry & Computer Aided Drug Designing and Drug Delivery
December 05-07, 2016 Phoenix, USA

S C Mehta
G R Medical College, India
Posters & Accepted Abstracts: Med chem
DOI: 10.4172/2161-0444.C1.028
Cancer is a disease of cells characterized by a defect in the normal control mechanisms that govern cell survival, proliferation and differentiation. It is the second most common cause of death in the United States. As our understanding of tumor biology and the molecules that make tumors grow and spread is expanding, new drugs that target these changes have emerged for the treatment of many different types of cancer. Targeted therapy is designed to target molecules in or on the tissue surrounding a tumor. Unlike standard chemotherapy drugs, targeted therapy drugs produce less severe side effects. Recently FDA approved Olaparib for the treatment of advanced ovarian cancer and Palbociclib for the treatment of advanced breast cancer. These drugs act by blocking a specific molecules responsible for the growth of cancer. Using the genetic makeup of different cancers new uses of existing drugs were also discovered. For example, the targeted therapy drug Ibrutinib, previously approved for chronic lymphocytic leukemia was found to be effective for the treatment of another type of blood cancer sharing the same genetic mutation,Waldestrom’s macrogloulinaemia (WM). Similarly, Sorafenib is a drug used to treat liver, kidney and thyroid cancer is effective against acute myeloid leukemia (AML) and Cabozantinib was found effective in advanced kidney cancer and non-small cell lung cancer (NSCLC). The present paper will discuss the different ways the targeted therapy can work and the types and common adverse effects of targeted therapy drugs.


image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

1-702-714-7001Extn: 9042

General Science

Andrea Jason

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001Extn: 9042

© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version